Staff Reports
The recent shake-up at the Food and Drug Administration is more than a personnel story. It is a warning sign. The departures of top officials, public visitor‑log entries showing ties to Arnold Ventures, and a blistering Senate hearing over rare‑disease reviews all point to a deeper problem: decisions at the FDA that matter to sick children and desperate families were made in a fog of inside influence and shifting standards. Patients deserve better than that.
Leadership shake‑up and Arnold Ventures’ footprint
Let’s be plain: former FDA leaders stepped down amid controversy. Vinay Prasad left his post at CBER and FDA Commissioner Marty Makary resigned, and the agency now lists Kyle Diamantas as acting commissioner and Karim Mikhail as acting CBER director. At the same time, public FDA records show Arnold Ventures — a well‑funded policy foundation — on the agency calendar for “collaboration opportunities.” People with Arnold ties briefly held or advised senior posts inside CBER. That is a fact. Whether those ties directly forced a policy change is harder to prove on paper, but the timing and the pattern deserve real scrutiny, not spin.
The human cost: rare disease and gene therapy decisions
What matters is what these decisions do to people. Under the recent review regime, several high‑profile cell and gene therapies ran into unexpected rejections or restrictions. Families watched as access to therapies like Sarepta’s Elevidys was narrowed, and promising Huntington’s and Duchenne programs hit regulatory roadblocks. The agency at one point demanded a full Phase 3 with sham surgery for a brain‑delivered therapy — a demand that left patients and some senators aghast. Call it bureaucratic caution, call it evidence rigor, but don’t pretend this puzzle hasn’t left real patients waiting and worse off.
Congress should stop the softball and demand answers
Senators aren’t just asking questions — they are holding hearings and public pressure is rising. That is good. The Senate Health, Education, Labor and Pensions committee and the Special Committee on Aging have a duty to dig into visitor logs, grant histories, and internal review memos. Vetting for new FDA leaders must be tough and public. No more opaque, closed‑door reversals on approvals. Advisory committees should be used, not sidelined. If the FDA wants public trust, it needs transparency and a return to open, expert review.
Restore balance: speed with safety, not ideology
We all want safe, effective medicines. We also must speed access for people who cannot wait. The solution is not trading one extreme for another. The FDA should accept sound, flexible evidence for rare diseases, while keeping clear guardrails. New appointees must say plainly that patients come first, not an ideological playbook. And Congress should require that outside meetings, grants, and conflicts are disclosed — every time. The medicine pipeline is America’s advantage. Let’s not let inside influence turn it into a slow‑moving roadblock for the sickest among us.
